Literature DB >> 11427605

Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.

J J Millichap1, E Pestova, F Siddiqui, G A Noskin, L R Peterson.   

Abstract

The association between fluoroquinolone susceptibility and DNA mutations coding for amino acid substitutions in the quinolone resistance-determining region was assessed with 44 clinical isolates of Streptococcus pneumoniae. Twenty-three strains bore at least one amino acid substitution. Only seven strains with mutations were suggested by diminished susceptibility to ciprofloxacin (MIC, > or =2 microg/ml).

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11427605      PMCID： PMC88221          DOI： 10.1128/JCM.39.7.2719-2721.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.

Authors:  A Kaneko; J Sasaki; M Shimadzu; A Kanayama; T Saika; I Kobayashi
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  M J Gill; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

Authors:  R Beyer; E Pestova; J J Millichap; V Stosor; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.

Authors:  E Pestova; R Beyer; N P Cianciotto; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

Review 6.  Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.

Authors:  L R Peterson
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

7.  Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.

Authors:  V J Heaton; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Primary targets of fluoroquinolones in Streptococcus pneumoniae.

Authors:  H Fukuda; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  4 in total

Review 1.  Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

Authors:  Benjamin J Epstein; John G Gums
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.

Authors:  Mark E Jones; Ian A Critchley; James A Karlowsky; Renée S Blosser-Middleton; Franz-Josef Schmitz; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Authors:  Angela B Brueggemann; Stacy L Coffman; Paul Rhomberg; Holly Huynh; Laurel Almer; Angela Nilius; Robert Flamm; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

4.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.